On September 18, WUXI APPTEC rose 3.43% in regular trading, trading at 205.0 HKD/share, with turnover of HKD 285 million. The stock extended its recent upward momentum after closing at 198.0 HKD the previous session.

The broader Life Sciences Tools and Services sector saw significant gains, with peer stocks rallying in tandem. INSILICO surged 10.51%, XTALPI rose 8.70%, GENSCRIPT BIO gained 6.82%, WUXI BIO climbed 3.19%, and WUXI XDC added 2.35%, reflecting a strong sector-wide linkage effect. Earlier this month, Morgan Stanley raised its target price for the company to 220 HKD with an overweight rating, while 44 brokerages named it a top pick in September.

On the fundamental side, the company reported first-half revenue of RMB 28.9 billion, up 38.94% year-over-year, with an order backlog of RMB 66.43 billion, growing 25.2%. Full-year continuing operations revenue guidance was raised to 35%-39% growth. Separately, the company has been steadily converting its RMB 6.78 billion zero-coupon convertible bonds due in 2027, with 1.94 million new H shares issued on September 17 at HKD 153 per share.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)